[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 38 of about 38
1. Tanaka K, Nakamura S, Matsumoto T, Hirakawa K, Yanaru-Fujisawa R, Onoyama K, Sakata H, Ohshima K, Yao T, Iida M: Long-term remission of primary gastric T cell lymphoma associated with human T lymphotropic virus type 1: a report of two cases and review of the literature. Intern Med; 2007;46(21):1783-7
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term remission of primary gastric T cell lymphoma associated with human T lymphotropic virus type 1: a report of two cases and review of the literature.
  • Two cases of primary gastric T-cell lymphoma associated with human T lymphotropic virus type 1 (HTLV-1) are presented.
  • Case 1 was a 54-year-old man who had multiple ulcerating tumors in the lower corpus and gastric antrum.
  • The patients were thus diagnosed as having primary gastric T-cell lymphoma associated with HTLV-1 of stage II(1).
  • Case 1 underwent total gastrectomy followed by chemotherapy, while Case 2 was treated by chemotherapy and radiotherapy.
  • Both patients have been in complete remission for more than 4 years (96 months in Case 1 and 50 months in Case 2) after the treatments.
  • Although primary gastric T-cell lymphomas associated with HTLV-1 is characterized by an extremely poor prognosis, the present cases suggest that in the early stage, long-term survival can possibly be achieved with appropriate treatments.
  • [MeSH-major] Lymphoma, T-Cell / therapy. Stomach Neoplasms / therapy

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17978535.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Viral
  •  go-up   go-down


2. Bariol C, Field A, Vickers CR, Ward R: Regression of gastric T cell lymphoma with eradication of Helicobacter pylori. Gut; 2001 Feb;48(2):269-71
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regression of gastric T cell lymphoma with eradication of Helicobacter pylori.
  • Helicobacter pylori is thought to be important in the pathogenesis of chronic active gastritis, peptic ulceration, gastric adenocarcinoma, and gastric B cell lymphoma of mucosa associated lymphoid tissue.
  • The mechanism of evolution from chronic gastritis to monoclonal B cell proliferation is not known but is thought to be dependent on antigen specific T cells to H pylori and its products.
  • Here, we report a case of gastric T cell lymphoma associated with chronic H pylori gastritis which regressed with eradication of the organism.
  • This is the first report of a gastric T cell lymphoma regressing with H pylori eradication, and suggests a causal link between primary gastric T cell lymphoma and this organism.
  • [MeSH-major] Helicobacter Infections / complications. Helicobacter pylori. Lymphoma, T-Cell / complications. Stomach Neoplasms / complications
  • [MeSH-minor] Adult. Biopsy. Drug Therapy, Combination. Humans. Male. Neoplasm Regression, Spontaneous. Neoplasm Staging. Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11156652.001).
  • [ISSN] 0017-5749
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1728204
  •  go-up   go-down


3. Nakamura S, Matsumoto T, Iida M, Yao T, Tsuneyoshi M: Primary gastrointestinal lymphoma in Japan: a clinicopathologic analysis of 455 patients with special reference to its time trends. Cancer; 2003 May 15;97(10):2462-73
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary gastrointestinal lymphoma in Japan: a clinicopathologic analysis of 455 patients with special reference to its time trends.
  • BACKGROUND: An optimal treatment modality for patients with primary gastrointestinal lymphoma has not yet been established.
  • This study aimed to elucidate the clinicopathologic features of this disease and the influence of therapeutic modalities on the prognosis in Japanese patients METHODS: The clinicopathologic features of 455 patients with primary gastrointestinal lymphoma were investigated retrospectively regarding treatment modalities and time trends.
  • RESULTS: This study comprised 342 patients (75%) with gastric lymphoma, 96 patients (22%) with intestinal lymphoma, and 17 patients (4%) with both gastric and intestinal lymphoma.
  • Two hundred thirty-one (51%) patients were classified as having low-grade B-cell lymphoma including 200 marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT) type, 185 (41%) patients were classified as having high-grade B-cell lymphoma including 76 diffuse large cell lymphoma plus MALT lymphoma, and 39 (9%) patients were classified as having T-cell lymphoma.
  • The frequency of nonsurgical treatment, including Helicobacter pylori eradication, chemotherapy, and radiation, increased during the latest decade.
  • Patients who received nonsurgical treatment showed a better overall survival than those treated by surgery, but event-free survival did not differ between two groups.
  • Cox multivariate analysis revealed that early stage, younger age, gastric localization, B-cell phenotype, and absence of B symptoms were independent prognostic factors for better overall and event-free survivals.
  • Mucosa-associated lymphoid tissue-derived lymphoma was also an independent prognostic factor for event-free survival, but not for overall survival.
  • CONCLUSIONS: Nonsurgical treatment may be an optimal therapeutic modality for patients with primary gastrointestinal lymphoma.
  • [MeSH-major] Gastrointestinal Neoplasms / epidemiology. Gastrointestinal Neoplasms / therapy. Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Japan / epidemiology. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 American Cancer Society.DOI 10.1002/cncr.11415
  • (PMID = 12733145.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Kahaleh M, Hermans P, Buset M, Dargent JL: Primary neutrophil-rich, CD30-positive anaplastic large cell lymphoma of the stomach: case report and review of the literature. Acta Gastroenterol Belg; 2002 Oct-Dec;65(4):237-40
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary neutrophil-rich, CD30-positive anaplastic large cell lymphoma of the stomach: case report and review of the literature.
  • Primary T-cell lymphoma of the stomach is a rare disease, most gastric lymphomas being of B-cell type.
  • Here we describe a unique case of primary neutrophil-rich CD30-positive anaplastic large cell lymphoma (ALCL) of the stomach that was treated and cured by combined chemotherapy.
  • According to our literature review, only 7 cases of primary gastric ALCL have been previously reported, none of them being of the neutrophil-rich subtype.
  • Although very peculiar in its histological presentation, which may simulate an inflammatory or carcinomatous process, the natural history as well as the clinical features of this unusual gastric lymphoma does not differ from the other reported cases of gastric ALCL.
  • [MeSH-major] Antigens, CD30 / analysis. Antineoplastic Combined Chemotherapy Protocols. Lymphoma, Large-Cell, Anaplastic / pathology. Neutrophils / immunology. Stomach Neoplasms / pathology

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12619433.001).
  • [ISSN] 1784-3227
  • [Journal-full-title] Acta gastro-enterologica Belgica
  • [ISO-abbreviation] Acta Gastroenterol. Belg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  • [Chemical-registry-number] 0 / Antigens, CD30; 0 / Antineoplastic Agents; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


5. Kobayashi K, Yokote T, Akioka T, Hara S, Oka S, Hirata Y, Miyoshi T, Tsuji M, Hanafusa T: [Primary gastric T-cell lymphoma with predominant bone marrow infiltration undergoing aggressive clinical course]. Gan To Kagaku Ryoho; 2007 Apr;34(4):647-51
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary gastric T-cell lymphoma with predominant bone marrow infiltration undergoing aggressive clinical course].
  • Upper gastroduodenal endoscopy revealed a gastric tumor in the greater curvature of the body.
  • Serum investigation showed human T-cell lymphotropic virus-1 (HTLV-1) antibody below 16 fold.
  • The diagnosis was HTLV-1 unassociated primary gastric T-cell lymphoma with bone marrow infiltration.
  • After undergoing oral chemotherapy with VP-16 at 25 mg/day, combination chemotherapy was initiated with vincristine 2 mg/day and dexamethasone 48 mg/day.
  • The man died with the aggressive clinical course after combination chemotherapy.
  • [MeSH-major] Bone Neoplasms / pathology. Leukemia-Lymphoma, Adult T-Cell / pathology. Lymphoma, T-Cell / pathology. Stomach Neoplasms / pathology

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17431359.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Antigens, CD3
  •  go-up   go-down


6. Takagi T, Saotome T: Chemotherapy with irinotecan (CPT-11), a topoisomerase-I inhibitor, for refractory and relapsed non-Hodgkin's lymphoma. Leuk Lymphoma; 2001 Aug;42(4):577-86
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy with irinotecan (CPT-11), a topoisomerase-I inhibitor, for refractory and relapsed non-Hodgkin's lymphoma.
  • Irinotecan hydrochloride (CPT-11), a DNA topoisomerase-I inhibitor, is now widely used in the treatment of various solid tumors, including colorectal, gastric, breast, lung, and ovarian cancer.
  • Despite the good response shown in the late phase-II study, CPT-11 was not often employed in the treatment of malignant lymphoma, mainly because of severe leukopenia and diarrhea caused by the recommended schedule: 40 mg/m2 of CPT-11 on days 1 to 3, 8 to 10, 15 to 17, then discontinued for at least 2 weeks.
  • Subsequently, a lower dose schedule (less than 40 mg/m2) was developed.
  • Our phase II trial employing a reduced dose of CPT-11 on days 1 and 2, plus ADM on day 3 with 3-week interval in patients with refractory and relapsed NHL showed a fairly good response of relapsed B-cell lymphoma and a substantial response of T-cell lymphoma with acceptable toxicity.
  • The combination of a topoisomerase-I inhibitor (CPT-11) and a topoisomerase-II inhibitor is an interesting concept for the treatment of NHL.
  • Another phase II trial in combination with CPT-11 and other anti-cancer drugs, particularly cisplatin or topoisomerase-II inhibitors, is warranted.
  • A superior salvage chemotherapy regimen could be found in the future by investigating combinations of low-dose CPT-11 and cisplatin or topoisomerase-II inhibitors.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / administration & dosage. Camptothecin / administration & dosage. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Clinical Trials as Topic. Humans. Salvage Therapy. Topoisomerase I Inhibitors

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11697485.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Topoisomerase I Inhibitors; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  • [Number-of-references] 42
  •  go-up   go-down


7. Ohno Y, Kosaka T, Muraoka I, Kanematsu T, Tsuru A, Kinoshita E, Moriuchi H: Remission of primary low-grade gastric lymphomas of the mucosa-associated lymphoid tissue type in immunocompromised pediatric patients. World J Gastroenterol; 2006 Apr 28;12(16):2625-8
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Remission of primary low-grade gastric lymphomas of the mucosa-associated lymphoid tissue type in immunocompromised pediatric patients.
  • We report the remission of primary gastric lymphoma of the mucosa-associated lymphoid tissue (MALT) type in two immunocompromised pediatric patients.
  • Examinations revealed gastric MALT with local invasion and lymph node involvement.
  • The MALT lesion spontaneously regressed over the next 24 months without any treatment for lymphoma.
  • Patient 2, a 6-year-old boy, underwent cord blood transplantation for the treatment of adrenoleukodystrophy.
  • Nausea and hematochezia appeared and further examinations revealed gastric MALT with H pylori gastritis.
  • Treatment consisting of medication for the H pylori infection alone eradicated the H pylori and completely resolved the patient's MALT lesion, as well.
  • In conclusion, gastric lymphoma of the MALT type can be cured by conservative treatment even in immunocompromised pediatric patients.
  • [MeSH-major] Lymphoma, Non-Hodgkin / therapy. Neoplasm Regression, Spontaneous. Stomach Neoplasms / therapy
  • [MeSH-minor] Adolescent. Child. Helicobacter Infections / complications. Helicobacter pylori / drug effects. Humans. Immunocompromised Host. Lymphoma, B-Cell, Marginal Zone. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Probl Pediatr Adolesc Health Care. 2001 Sep;31(8):247-66 [11595896.001]
  • [Cites] Transplantation. 2001 Apr 27;71(8):1172-5 [11374421.001]
  • [Cites] Aliment Pharmacol Ther. 2002 Feb;16(2):167-80 [11860399.001]
  • [Cites] Am J Gastroenterol. 2002 Feb;97(2):292-7 [11866264.001]
  • [Cites] Gut. 2002 May;50 Suppl 3:III19-24 [11953328.001]
  • [Cites] J Heart Lung Transplant. 2002 Sep;21(9):1044-5 [12231377.001]
  • [Cites] Transplantation. 2003 Jan 27;75(2):225-8 [12548128.001]
  • [Cites] Gut. 2004 Jan;53(1):34-7 [14684573.001]
  • [Cites] Pediatr Dev Pathol. 2004 Jul-Aug;7(4):407-13 [15455481.001]
  • [Cites] Lancet. 1991 Nov 9;338(8776):1175-6 [1682595.001]
  • [Cites] Lancet. 1993 Sep 4;342(8871):571-4 [8102718.001]
  • [Cites] Med Pediatr Oncol. 1994;22(1):66-7 [8232084.001]
  • [Cites] Lancet. 1994 Apr 30;343(8905):1098-9 [7909113.001]
  • [Cites] Gastroenterology. 1995 Sep;109(3):973-7 [7657127.001]
  • [Cites] Histopathology. 1996 Feb;28(2):129-34 [8834520.001]
  • [Cites] South Med J. 1997 Jun;90(6):570-6; quiz 577 [9191731.001]
  • [Cites] Gastroenterology. 1997 Dec;113(6 Suppl):S61-4 [9394762.001]
  • [Cites] Am J Clin Pathol. 1999 Jan;111(1 Suppl 1):S126-32 [9894477.001]
  • [Cites] Ann Intern Med. 1999 Jul 20;131(2):88-95 [10419446.001]
  • [Cites] Pediatr Pathol Mol Med. 2002 Jan-Feb;21(1):31-9 [11842977.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3835-49 [10577857.001]
  • [Cites] Am J Surg Pathol. 2000 Jan;24(1):100-6 [10632493.001]
  • [Cites] Arch Immunol Ther Exp (Warsz). 2000;48(3):201-4 [10912626.001]
  • [Cites] Gut. 2001 Mar;48(3):297-303 [11171816.001]
  • [Cites] Gut. 2001 Apr;48(4):454-60 [11247887.001]
  • [Cites] Pediatr Radiol. 2002 Feb;32(2):82-7 [11819070.001]
  • (PMID = 16688815.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4088002
  •  go-up   go-down


8. Betticher DC, Martinelli G, Radford JA, Kaufmann M, Dyer MJ, Kaiser U, Aulitzky WE, Beck J, von Rohr A, Kovascovics T, Cogliatti SB, Cina S, Maibach R, Cerny T, Linch DC: Sequential high dose chemotherapy as initial treatment for aggressive sub-types of non-Hodgkin lymphoma: results of the international randomized phase III trial (MISTRAL). Ann Oncol; 2006 Oct;17(10):1546-52
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sequential high dose chemotherapy as initial treatment for aggressive sub-types of non-Hodgkin lymphoma: results of the international randomized phase III trial (MISTRAL).
  • INTRODUCTION: Sequential high dose (SHiDo) chemotherapy with stem cell support has been shown to prolong the event-free survival in patients with diffuse large B-cell lymphoma.
  • The primary endpoint was overall survival.
  • Toxicity grades 3+4 were more pronounced in the SHiDo-arm with 13% versus 3% of patients with fever; 34% versus 13% with infections; 13% versus 2% with esophagitis/dysphagia/gastric ulcer.
  • After a median observation time of 48 months, there was no difference in overall survival at 3 years, with 46% for SHiDo and 53% for CHOP (P = 0.48).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma, Non-Hodgkin / drug therapy. Neoadjuvant Therapy / methods
  • [MeSH-minor] Adolescent. Adult. Cyclophosphamide / adverse effects. Disease-Free Survival. Dose-Response Relationship, Drug. Doxorubicin / adverse effects. Drug Administration Schedule. Feasibility Studies. Female. Humans. Male. Middle Aged. Multivariate Analysis. Prednisone / adverse effects. Recurrence. Salvage Therapy. Survival Analysis. Vincristine / adverse effects


9. Park YH, Kim WS, Bang SM, Lee SI, Kang HJ, Na II, Yang SH, Lee SS, Uhm JE, Kwon JM, Kim K, Jung CW, Park K, Ko YH, Ryoo BY: Primary gastric lymphoma of T-cell origin: clinicopathologic features and treatment outcome. Leuk Res; 2006 Oct;30(10):1253-8
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary gastric lymphoma of T-cell origin: clinicopathologic features and treatment outcome.
  • We conducted a retrospective analysis to investigate the natural history and the clinical outcome after treatment of primary gastric lymphoma of T-cell origin.
  • Seventeen cases of T-cell origin among 444 primary gastric lymphoma patients were analyzed.
  • This study showed that the incidence of this subtype of T-cell gastric lymphoma was very rare, and had poor prognosis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, T-Cell / drug therapy. Lymphoma, T-Cell / pathology. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Cyclophosphamide / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Humans. Male. Middle Aged. Prednisone / administration & dosage. Retrospective Studies. Survival Analysis. Time Factors. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16529813.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


10. Yachida S, Sasako M, Tobinai K, Matsuno Y, Shimoda T: Successful treatment of a primary gastric T-cell lymphoma lacking the human T-cell leukemia virus type 1. Hepatogastroenterology; 2010 Mar-Apr;57(98):383-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of a primary gastric T-cell lymphoma lacking the human T-cell leukemia virus type 1.
  • Primary gastric lymphomas generally are of B-cell lineage.
  • Among the previously reported cases of exceptional primary gastric T-cell lymphomas, most demonstrate evidence of human T-cell leukemia virus type 1 (HTLV-1) infection with a poor prognosis.
  • The present study is a report of a rare case of primary gastric T-cell lymphoma without HTLV-1 which could be successfully treated with surgical resection and adjuvant chemotherapy.
  • Radiographic and endoscopic examinations revealed an ill-demarcated ulcerative lesion in the stomach, and a biopsy specimen confirmed high-grade lymphoma.
  • Histological examination of the gastric lesion revealed a malignant lymphoma, diffuse large cell type, with lymph nodal involvement.
  • On immunohistochemistry, tumor cells were positive for CD3, CD4 and CD30, but negative for CD8, CD20 and CD56, implying a T-cell nature.
  • Following surgery, the patient received 8 cycles of chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisolone/CHOP).
  • To date the patient has been free of recurrence for 86 months without further treatment.
  • Review of previously reported cases of primary gastric T-cell lymphoma indicates that the prognosis is better without than with HTLV-1.
  • We conclude that primary gastric T-cell lymphomas without HTLV-1 should be managed in the same way as the more common diffuse large B-cell type gastric lymphomas.
  • [MeSH-major] Lymphoma, T-Cell / drug therapy. Lymphoma, T-Cell / surgery. Stomach Neoplasms / drug therapy. Stomach Neoplasms / surgery
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Gastrectomy. Human T-lymphotropic virus 1. Humans. Lymph Node Excision. Male. Middle Aged. Prednisone / therapeutic use. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • Genetic Alliance. consumer health - Human T-cell leukemia virus type 1.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20583449.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Greece
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  • [Number-of-references] 25
  •  go-up   go-down


11. Gotoh M, Kitahara T, Iguchi T, Izumi M, Mukai K, Ohyashiki K: [HIV-related multiple non-Hodgkin lymphomas]. Rinsho Ketsueki; 2008 Nov;49(11):1552-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [HIV-related multiple non-Hodgkin lymphomas].
  • He was HIV-positive, and had gastric diffuse large B-cell lymphoma and renal T-cell anaplastic large cell lymphoma (T-ALCL).
  • The patient received anti-retroviral therapy, and started the CHOP regimen for the double lymphomas, resulting in transient improvement.
  • However, fever again appeared during HAART and CHOP treatment, and a right inguinal subcutaneous lesion appeared.
  • Biopsy specimen demonstrated null cell ALCL, and this patient demonstrated multiple lymphomas.
  • This case suggested that cancer generation was promoted by low immunity, although it is known that ambivalent tumors such as non-Hodgkin lymphomas can occur frequently.
  • [MeSH-major] Lymphoma, AIDS-Related / diagnosis. Lymphoma, B-Cell / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large-Cell, Anaplastic / diagnosis. Lymphoma, T-Cell / diagnosis. Neoplasms, Multiple Primary. Stomach Neoplasms / diagnosis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Humans. Kidney Neoplasms / diagnosis. Kidney Neoplasms / drug therapy. Lymphocytes, Null. Male. Prednisolone / administration & dosage. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19047787.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  •  go-up   go-down


12. Schmidt WP, Schmitz N, Sonnen R: Conservative management of gastric lymphoma: the treatment option of choice. Leuk Lymphoma; 2004 Sep;45(9):1847-52
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conservative management of gastric lymphoma: the treatment option of choice.
  • The study was initiated to assess the safety and effectiveness of primary chemotherapy (CHT) followed by radiotherapy (RT) compared to surgery prior to CHT and/or RT in the management of localized gastric lymphoma.
  • Sixty patients received primary CHT followed by extended field or involved field RT.
  • Thirty-two patients had undergone primary surgery prior to referral and were treated with curative or consolidative CHT and/or RT.
  • MALT histology was present in 25, diffuse large-cell in 62, lymphoplasmocytic in 4 cases and follicular histology in 1 case.
  • Five-year disease-specific survival was 93% both after primary CHT and after primary surgery (P = 0.8).
  • No patient experienced gastric perforation or bleeding during CHT.
  • Primary CHT of localized gastric lymphoma is associated with a low risk of treatment-related complications.
  • To avoid long-term sequelae after gastric resection, primary CHT is recommended as standard initial treatment in localized gastric lymphoma.
  • [MeSH-major] Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / radiotherapy. Stomach Neoplasms / drug therapy. Stomach Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 Taylor and Francis Ltd
  • (PMID = 15223645.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


13. Parvez T, Behani A, Ali A: Primary gastric lymphoma. J Coll Physicians Surg Pak; 2007 Jan;17(1):36-40
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary gastric lymphoma.
  • OBJECTIVE: To evaluate the clinico-pathological status of Primary Gastric Lymphoma (PGL) at presentation in King Fahad Hospital, Madina Munawra, Kingdom of Saudi Arabia (KSA).
  • According to the treatment modality, different groups were established.
  • Any other histopathological type was excluded from the study.
  • RESULTS: All cases were Non-Hodgkin Lymphoma (NHL).
  • Diffuse large cell lymphoma was found in 12 (55%), poorly differentiated lymphoma in 3 (14%) and diffuse mixed in 7 (32%).
  • Sixteen (73%) patients underwent chemotherapy with some surgical resection, in 5 (23%) surgical procedure was palliative bypass and 11 (50%) had partial gastrectomy.
  • Three (14%) had only chemotherapy after endoscopic biopsy.
  • CONCLUSION: PGL is usually of NHL type, presenting in the sixth decade, and can be successfully treated with both surgery and chemotherapy when patients presented at stage II.
  • Chemotherapy after sub-total gastrectomy or biopsy was the best treatment option.
  • [MeSH-major] Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / therapy. Stomach Neoplasms / diagnosis. Stomach Neoplasms / therapy
  • [MeSH-minor] Abdominal Pain / etiology. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Female. Gastrectomy. Humans. Male. Middle Aged. Prednisone / therapeutic use. Saudi Arabia. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17204218.001).
  • [ISSN] 1022-386X
  • [Journal-full-title] Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • [ISO-abbreviation] J Coll Physicians Surg Pak
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


14. Morgner A, Miehlke S, Fischbach W, Schmitt W, Müller-Hermelink H, Greiner A, Thiede C, Schetelig J, Neubauer A, Stolte M, Ehninger G, Bayerdörffer E: Complete remission of primary high-grade B-cell gastric lymphoma after cure of Helicobacter pylori infection. J Clin Oncol; 2001 Apr 01;19(7):2041-8
Hazardous Substances Data Bank. OMEPRAZOLE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete remission of primary high-grade B-cell gastric lymphoma after cure of Helicobacter pylori infection.
  • PURPOSE: Treatment of low-grade gastric mucosa-associated lymphoid tissue lymphoma by eradication of Helicobacter pylori is reported to result in complete lymphoma remission in approximately 75% of cases.
  • The effect that cure of the infection has on the course of a primary high-grade gastric lymphoma is largely uncertain.
  • The aim of this study was to report the effect of cure of H pylori infection exerted in patients with high-grade B-cell gastric lymphoma.
  • PATIENTS AND METHODS: Eight patients (4 males and 4 females; age range, 26 to 85 years) with H pylori infection and high-grade lymphoma received eradication therapy before planned treatment.
  • The effect of H pylori eradication on the course of high-grade lymphoma was assessed by analysis of surgical specimens (n = 2) or endoscopic biopsies (n = 6).
  • RESULTS: H pylori eradication was successful in all patients and led to complete remission of the lymphoma in seven patients.
  • Two patients were referred to surgery, one of whom (stage II(1E)) had lymph node involvement, and the histologic work-up of the resected stomach revealed residual infiltrates of a low-grade lymphoma, which prompted consolidation chemotherapy.
  • In one patient (initially stage I(1E)), abdominal lymphoma developed 6 months after eradication therapy, which regressed completely after chemotherapy.
  • In four patients, no further treatment was given.
  • CONCLUSION: Primary high-grade B-cell gastric lymphoma in stages I(E) through II(E1) associated with H pylori may regress completely after successful cure of the infection.
  • Prospective trials are needed to investigate this treatment in larger numbers of patients.
  • [MeSH-major] Helicobacter Infections / complications. Helicobacter Infections / drug therapy. Helicobacter pylori. Lymphoma, B-Cell / microbiology. Lymphoma, Non-Hodgkin / microbiology. Stomach Neoplasms / microbiology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Amoxicillin / therapeutic use. Anti-Ulcer Agents / therapeutic use. Cell Transformation, Neoplastic. Female. Humans. Lymphoma, B-Cell, Marginal Zone / drug therapy. Lymphoma, B-Cell, Marginal Zone / microbiology. Lymphoma, B-Cell, Marginal Zone / pathology. Male. Middle Aged. Omeprazole / therapeutic use. Penicillins / therapeutic use. Remission Induction / methods. Retrospective Studies

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. AMOXICILLIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11283137.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Ulcer Agents; 0 / Penicillins; 804826J2HU / Amoxicillin; KG60484QX9 / Omeprazole
  •  go-up   go-down


15. Iwamizu-Watanabe S, Yamashita Y, Yatabe Y, Nakamura S, Mori N: Frequent expression of CD30 antigen in the primary gastric non-B, non-Hodgkin lymphomas. Pathol Int; 2004 Jul;54(7):503-9
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequent expression of CD30 antigen in the primary gastric non-B, non-Hodgkin lymphomas.
  • Most primary gastric lymphomas are of B-cell origin.
  • Fourteen cases of primary gastric non-B, non-Hodgkin lymphomas were studied to evaluate their clinicopathological and immunophenotypic findings.
  • Most patients underwent surgery either with or without chemotherapy, exhibiting a 5 year survival rate of 57.5%.
  • Morphologically, the neoplastic cells showed various histological features, such as anaplastic large cell lymphoma (ALCL) (n = 3), peripheral T-cell lymphoma, unspecified, large (n = 4), medium-sized (n = 2) and mixed cell (n = 5).
  • Two cases displayed a non-B, non-T cell phenotype, whereas the remaining cases displayed a T-cell phenotype.
  • In one case, anaplastic large cell lymphoma kinase (ALK) was identified with immunostaining and chromosomal rearrangement of ALK was detected by fluorescence in situ hybridization (FISH).
  • In conclusion, although the mechanism of CD30 expression is unknown, primary gastric non-B, non-Hodgkin lymphomas tend to express CD30.
  • [MeSH-major] Antigens, CD30 / metabolism. Lymphoma, Large-Cell, Anaplastic / metabolism. Lymphoma, Non-Hodgkin / metabolism. Lymphoma, T-Cell, Peripheral / metabolism. Stomach Neoplasms / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15189504.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antigens, CD30
  •  go-up   go-down


16. Coffey J, Hodgson DC, Gospodarowicz MK: Therapy of non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging; 2003 Jun;30 Suppl 1:S28-36
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapy of non-Hodgkin's lymphoma.
  • Non-Hodgkin's lymphomas are a heterogeneous group of malignancies of the lymphoid system.
  • The WHO classification of hematopoietic and lymphoid tumours classifies lymphomas into B-cell and T-cell neoplasms.
  • B-cell lymphomas account for more than 85% of all lymphomas.
  • The two most common histologic disease entities are follicular lymphomas and diffuse large B-cell lymphomas.
  • Radiation therapy is used for stage I and II disease, while alkylating agent chemotherapy, immunotherapy and radioimmunotherapy are most frequently used in stage III and IV disease that requires treatment.
  • Most patients with follicular lymphoma enjoy prolonged survival, but at present there is no evidence that those with stage III and IV follicular lymphoma can be cured.
  • Diffuse large B-cell lymphomas serve as a paradigm for treating aggressive lymphomas.
  • Stage I and II diffuse large cell lymphomas are generally treated with combined modality therapy with doxorubicin-based chemotherapy followed by involved field radiation therapy, while those with stage III and IV disease are treated with chemotherapy alone.
  • Patients who fail initial management are treated with further chemotherapy.
  • High-dose chemotherapy with stem cell rescue has been shown to be particularly effective as salvage treatment for diffuse large cell lymphomas.
  • The management of a heterogeneous group of primary extranodal lymphomas in general follows the above treatment principles, with additional treatment being required for those with a high risk of CNS failures, or involvement of contralateral paired organs.
  • The management of MALT lymphomas, especially gastric MALT lymphoma, deserves special attention because of the high response rate to Helicobacter pylori eradication therapy.
  • [MeSH-major] Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow Transplantation. Combined Modality Therapy. Female. Humans. Immunotherapy. Male. Neoplasm Staging. Peripheral Blood Stem Cell Transplantation. Radioimmunotherapy. Transplantation, Autologous

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1993 Sep 30;329(14 ):987-94 [8141877.001]
  • [Cites] Ann Oncol. 2002 Sep;13(9):1341-6 [12196358.001]
  • [Cites] Important Adv Oncol. 1994;:117-29 [8206485.001]
  • [Cites] N Engl J Med. 1993 Nov 25;329(22):1608-14 [8232429.001]
  • [Cites] N Engl J Med. 1993 Apr 8;328(14):1002-6 [7680764.001]
  • [Cites] Br J Cancer. 2001 Jul 6;85(1):29-35 [11437398.001]
  • [Cites] J Clin Oncol. 2002 Oct 1;20(19):4022-31 [12351600.001]
  • [Cites] J Clin Oncol. 2000 May;18(10 ):2010-6 [10811664.001]
  • [Cites] Br J Cancer. 1993 Apr;67(4):792-7 [8471438.001]
  • [Cites] N Engl J Med. 1995 Dec 7;333(23):1540-5 [7477169.001]
  • [Cites] J Natl Cancer Inst. 2001 Jun 6;93(11):824-42 [11390532.001]
  • [Cites] J Clin Oncol. 2002 May 15;20(10 ):2453-63 [12011122.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Leuk Lymphoma. 1992 May;7(1-2):135-8 [1472924.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Aug 1;50(5):1258-64 [11483337.001]
  • [Cites] J Clin Oncol. 2002 Aug 15;20(16):3545-57 [12177115.001]
  • [Cites] Lancet. 1993 Dec 18-25;342(8886-8887):1514-6 [7902900.001]
  • [Cites] Gut. 2002 May;50 Suppl 3:III19-24 [11953328.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):268-76 [10458242.001]
  • [Cites] Radiother Oncol. 1995 Sep;36(3):167-71 [8532901.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Aug 1;53(5):1337-49 [12128137.001]
  • [Cites] Ann Oncol. 2002 Sep;13(9):1347-55 [12196359.001]
  • [Cites] Eur J Cancer. 2001 Sep;37(13):1659-67 [11527693.001]
  • [Cites] J Clin Oncol. 2000 Mar;18(5):947-55 [10694543.001]
  • [Cites] N Engl J Med. 1998 Jul 2;339(1):21-6 [9647875.001]
  • [Cites] Cancer. 1982 May 15;49(10):2112-35 [6896167.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Mar 1;52(3):643-51 [11849785.001]
  • [Cites] J Clin Oncol. 1996 Apr;14(4):1282-90 [8648385.001]
  • [Cites] Lancet. 1993 Sep 4;342(8871):575-7 [8102719.001]
  • [Cites] Ann Hematol. 2001;80 Suppl 3:B66-72 [11757712.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):280-2 [11807154.001]
  • [Cites] N Engl J Med. 2002 Jul 11;347(2):89-94 [12110736.001]
  • [Cites] Lancet. 2001 Jan 6;357(9249):39-40 [11197361.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jul 1;50(3):743-9 [11395243.001]
  • [Cites] Blood. 1994 Jun 15;83(12):3800-7 [8204898.001]
  • [Cites] Blood. 1997 Jun 1;89(11):3909-18 [9166827.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2780-95 [9704731.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2817-24 [9704734.001]
  • [Cites] Cancer Res. 1971 Nov;31(11):1860-1 [5121694.001]
  • [Cites] Int J Cancer. 1997 Nov 27;73(5):645-50 [9398040.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2825-33 [9704735.001]
  • [Cites] J Natl Cancer Inst. 2000 Aug 2;92(15):1240-51 [10922409.001]
  • [Cites] Cancer. 1983 Oct 15;52(8):1410-6 [6193858.001]
  • [Cites] Cancer. 2002 Apr 1;94(7):2015-23 [11932904.001]
  • [Cites] Blood. 2000 Feb 1;95(3):802-6 [10648389.001]
  • (PMID = 12692688.001).
  • [ISSN] 1619-7070
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 54
  •  go-up   go-down


17. Tóth I, Nagy Z, Barna T, Szucs G: [Changes in the treatment strategy of primary gastric lymphoma]. Magy Seb; 2007 Apr;60(2):79-86
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Changes in the treatment strategy of primary gastric lymphoma].
  • Nowadays the management strategy for primary gastric lymphoma is undergoing change due to the effectiveness of chemotherapy and immunotherapy.
  • While earlier surgical resection was the primary treatment and chemotherapy was only a follow-on procedure, at the present time this arrangement seems to have been reversed.
  • Early stage low-grade MALT lymphoma can be treated with Helicobacter pylori eradication.
  • Total or subtotal gastrectomy with D2 lymphadenectomy and with adjuvant chemotherapy in R1 situation is proposed up to stage II.1.
  • The strategy is similar in the case of high-grade gastric lymphoma, but resection is useful only in those cases when one can be assured the result will be an R0 situation.
  • The diagnosis of lymphoma can often only be made after the operation.
  • In the 6-year period between 1st January 2000 and 31st December 2005 we treated 38 patients for primary gastric lymphoma.
  • The diagnosis of lymphoma was known preoperatively only in one case.
  • Nowadays surgery seems to be only secondary to chemotherapy and immuno-chemotherapy in the treatment of primary gastric MALT lymphoma.
  • [MeSH-major] Anti-Bacterial Agents / therapeutic use. Antineoplastic Agents / therapeutic use. Gastrectomy. Immunotherapy. Lymphoma, Non-Hodgkin / therapy. Stomach Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Helicobacter Infections / complications. Helicobacter Infections / drug therapy. Helicobacter pylori / drug effects. Humans. Lymph Node Excision. Lymphoma, B-Cell, Marginal Zone / microbiology. Lymphoma, B-Cell, Marginal Zone / therapy. Male. Middle Aged. Neoplasm Staging. Retrospective Studies

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • MedlinePlus Health Information. consumer health - Antibiotics.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17649848.001).
  • [ISSN] 0025-0295
  • [Journal-full-title] Magyar sebészet
  • [ISO-abbreviation] Magy Seb
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Antineoplastic Agents
  •  go-up   go-down


18. Niitsu N, Nakamine H, Kohri M, Hayama M, Tamaru J, Iwabuchi K, Tanabe S, Horie R, Higashihara M: Primary gastric T-cell lymphoma not associated with human T-lymphotropic virus type I: a case report and review of the literature. Ann Hematol; 2003 Mar;82(3):197-202
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary gastric T-cell lymphoma not associated with human T-lymphotropic virus type I: a case report and review of the literature.
  • Primary gastric T-cell lymphoma (PGTL) not associated with human T-lymphotropic virus type I (HTLV-I) is extremely rare and such a case is reported herein.
  • The patient was a 58-year-old Japanese male presenting with submucosal tumor of the stomach identified on endoscopic examination.
  • The lesion was diagnosed as non-Hodgkin's lymphoma by endoscopic biopsy and classified as peripheral T-cell lymphoma, unspecified, due to clonal rearrangement of the T-cell receptor beta (TCR) gene and expression of TCR beta protein in the absence of B-cell genotypes and phenotypes.
  • Unlike previously reported cases of HTLV-I-unassociated PGTL, lymphoma in the current case was characterized histologically as "low grade" and phenotypically as CD4+, TIA-1+, granzyme B+, and CD103-.
  • The lymphoma responded well to chemotherapy and radiation, and the patient was well with no detectable disease 10 months after initiation of therapy.
  • A review of patients with PGTL in the literature revealed a few long-term survivors, and the investigation of therapeutic strategies for PGTL is, therefore, necessary.
  • [MeSH-major] Lymphoma, T-Cell / pathology. Stomach Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Blotting, Southern. Bone Marrow / pathology. Gene Rearrangement, beta-Chain T-Cell Antigen Receptor. Humans. Immunophenotyping. Male. Middle Aged. Neoplasm Staging. Radiotherapy. Receptors, Antigen, T-Cell, alpha-beta / genetics

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12634958.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Receptors, Antigen, T-Cell, alpha-beta
  • [Number-of-references] 23
  •  go-up   go-down


19. Au WY, Yeung CK, Chan HH, Wong RW, Shek TW: CD30-positive cutaneous T-cell lymphoma with concurrent solid tumour. Br J Dermatol; 2002 Jun;146(6):1091-5
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD30-positive cutaneous T-cell lymphoma with concurrent solid tumour.
  • Extranodal CD30+ T-cell lymphomas seldom carry classical t(2;5) translocation and are usually anaplastic large cell lymphoma kinase protein negative.
  • The prognosis of CD30+ cutaneous T-cell lymphoma (CTCL) is good in the absence of nodal primary or disseminated disease.
  • Although an increased incidence of solid tumours has been reported in patients with CD30+ non-Hodgkin lymphoma of the skin, reports of concurrent malignancies are rare in CD30+ CTCL.
  • We report two patients with CD30+ CTCL who, respectively, had concurrent disseminated gastric carcinoma and bilateral ovarian teratoma.
  • The CTCL responded completely to chemotherapy in one patient, who eventually succumbed to gastric cancer.
  • A possible relationship between the lymphoma and the solid tumours is discussed.
  • [MeSH-major] Antigens, CD30 / analysis. Antigens, Neoplasm / analysis. Lymphoma, T-Cell, Cutaneous / immunology. Neoplasms, Multiple Primary / immunology. Skin Neoplasms / immunology. Stomach Neoplasms / immunology. Uterine Neoplasms / immunology

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12072086.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD30; 0 / Antigens, Neoplasm
  •  go-up   go-down


20. Chott A, Raderer M: New developments in extracutaneous lymphomas. Semin Cutan Med Surg; 2000 Jun;19(2):149-56
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The recently proposed World Health Organization classification of neoplastic diseases of the lymphoid tissues is based on the principles of the Revised European-American Classification of Lymphoid Neoplasms introduced in 1994.
  • Use of these classifications implies a new approach to lymphoma diagnosis, especially because of the inclusion of clinical data among which the site of involvement (nodal v extranodal) is very important.
  • Recent technical advances allowing molecular biological investigations on the single cell level helped gain new insights into the cellular origin of B-cell lymphomas.
  • Tumor cells of the majority of B-cell non-Hodgkin's lymphomas (NHL) harbor somatically mutated immunoglobulin variable region genes, and are therefore derived from germinal center B cells or their descendants.
  • The same is true for Hodgkin's disease, which (at least in the majority of cases) is a germinal center derived B-cell lymphoma.
  • Significant news on the molecular pathogenesis of NHL include the prognostically relevant dichotomy of B-CLL, the involvement of translocations affecting 3q27 in 20% to 40% of diffuse large B-cell lymphomas (DLBCL), the prognostical implication of the t(2;5) in anaplastic large cell lymphoma, and detection of the t(11;18) in gastric mucosa-associated lymphoid tissue (MALT)-type lymphoma.
  • A major step forward with regard to gastric MALT-type lymphoma therapy was the discovery of a causal relationship between Helicobacter pylori infection and lymphomagenesis.
  • Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy remains the golden standard for DLBCL treatment.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. B-Lymphocytes / metabolism. Cell Transformation, Neoplastic. Lymphoma, B-Cell / genetics. Mutation. Translocation, Genetic
  • [MeSH-minor] Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Hodgkin Disease / genetics. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Lymphoma, B-Cell, Marginal Zone / genetics. Lymphoma, Large B-Cell, Diffuse / genetics. Prognosis. Rituximab. Stomach Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10892718.001).
  • [ISSN] 1085-5629
  • [Journal-full-title] Seminars in cutaneous medicine and surgery
  • [ISO-abbreviation] Semin Cutan Med Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 38
  •  go-up   go-down


21. Küpeli S, Varan A, Demir H, Aydin B, Yüce A, Büyükpamukçu M: Association of Helicobacter pylori and childhood lymphoma. J Pediatr Hematol Oncol; 2007 May;29(5):301-4
MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of Helicobacter pylori and childhood lymphoma.
  • We aimed to estimate the frequency of association between non-Hodgkin lymphoma (NHL) with abdominal, gastric, or intestinal involvement and Helicobacter pylori in childhood.
  • Patients who were given chemotherapy previously or who received H. pylori eradication therapy were excluded from the study.
  • They had extensive abdominal, gastric, and/or intestinal involvement.
  • Ten had high-grade B-cell lymphoma.
  • First patient had T-cell lymphoma and stage IV disease with involvement in stomach, mediastinum, peripheral lymph nodes, and bone marrow.
  • The second one had anaplastic large cell lymphoma exclusively in abdominal lymph nodes.
  • Last patient had Burkitt lymphoma and stage IV disease, with primary tumor localization in abdominal lymph nodes, liver, and kidneys.
  • We did not find any positive test results in the other 12 patients with intestinal, stomach, or abdominal disease.
  • [MeSH-major] Gastrointestinal Neoplasms / epidemiology. Helicobacter Infections / epidemiology. Helicobacter pylori / isolation & purification. Lymphoma, B-Cell / epidemiology. Lymphoma, Non-Hodgkin / epidemiology
  • [MeSH-minor] Adolescent. Anti-Bacterial Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Combined Modality Therapy. Drug Therapy, Combination. Female. Humans. Male. Neoplasm Staging. Prospective Studies. Recurrence. Risk Assessment. Sampling Studies. Treatment Outcome. Turkey / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17483706.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  •  go-up   go-down


22. Morgner A, Lehn N, Andersen LP, Thiede C, Bennedsen M, Trebesius K, Neubauer B, Neubauer A, Stolte M, Bayerdörffer E: Helicobacter heilmannii-associated primary gastric low-grade MALT lymphoma: complete remission after curing the infection. Gastroenterology; 2000 May;118(5):821-8
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Helicobacter heilmannii-associated primary gastric low-grade MALT lymphoma: complete remission after curing the infection.
  • BACKGROUND & AIMS: Cure of Helicobacter pylori infection may lead to complete remission of associated low-grade mucosa-associated lymphoid tissue (MALT) lymphoma in stage EI.
  • This study investigated whether Helicobacter heilmannii infection-associated primary gastric MALT lymphoma will regress after cure of the infection.
  • METHODS: H. heilmannii-induced gastritis was diagnosed histologically, by a new specific immunoglobulin G enzyme-linked immunosorbent assay, and with 16S ribosomal RNA amplification and sequencing in 5 consecutive patients with primary gastric MALT lymphoma clinical stage EI.
  • Patients received 40 mg omeprazole and 750 mg amoxicillin 3 times per day for 14 days.
  • Polymerase chain reaction (PCR) was used to detect rearrangement of immunoglobulin heavy-chain genes before treatment and during follow-up.
  • Treatment resulted in the cure of H. heilmannii infection in each case and complete histological and endoscopic remission of the tumors.
  • Three of 5 patients showed monoclonal B cells before treatment, 2 of whom remained PCR positive.
  • Within a median follow-up period of 24 months, no relapse of the lymphoma or reinfection with H. heilmannii occurred.
  • CONCLUSIONS: These data suggest that gastric MALT lymphoma may arise in patients with H. heilmannii infection.
  • Cure of this infection may lead to complete remission of the MALT lymphoma.
  • [MeSH-major] Helicobacter. Helicobacter Infections / drug therapy. Lymphoma, B-Cell, Marginal Zone / pathology. Lymphoma, Non-Hodgkin / pathology. Stomach Neoplasms / pathology

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10784580.001).
  • [ISSN] 0016-5085
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  •  go-up   go-down


23. Zucca E, Gregorini A, Cavalli F: Management of non-Hodgkin lymphomas arising at extranodal sites. Ther Umsch; 2010 Oct;67(10):517-25
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of non-Hodgkin lymphomas arising at extranodal sites.
  • Primary extranodal lymphomas are relatively rare non-Hodgkin lymphoma presentations with either no or only "minor" nodal involvement along with a clinically "dominant" extranodal component, to which primary treatment must often be directed.
  • In addition to the histological subtype, the primary organ of origin represents the most significant prognostic factor due to differences in natural history and, mainly, in management strategies related to organ-specific problems.
  • In principle, as for primary nodal disease, treatment strategies depends on the patient's clinical conditions, the extent and/or location of the disease, and the histological type.
  • In general, for stage I and II disease with low tumor burden, local therapy is a relevant option both for cure and local control.
  • Localizations with particularly poor survival are the enteropathy-type T-cell lymphoma, the primary testicular diffuse large B-cell lymphoma, and the primary CNS Lymphoma.
  • However, recent studies have shown that site-tailored treatment strategies in testis and brain lymphoma may result in a significant outcome improvement.
  • Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) is the most common indolent subtype.
  • This lymphoma usually arises in mucosal sites where lymphocytes are not normally present and where a lymphoid infiltration is acquired in response to either chronic infectious conditions or autoimmune processes: Helicobacter pylori gastritis, Hashimoto's thyroiditis, Sjögren syndrome.
  • Indeed, a pathogenetic link between gastric MALT lymphoma and H. pylori is strongly suggested by the regression of gastric MALT lymphoma (in approx.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / radiotherapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Combined Modality Therapy. Disease Progression. Drug Delivery Systems. Humans. Neoplasm Staging. Prognosis. Radiotherapy, Adjuvant. Tumor Burden

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20886458.001).
  • [ISSN] 0040-5930
  • [Journal-full-title] Therapeutische Umschau. Revue thérapeutique
  • [ISO-abbreviation] Ther Umsch
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


24. Alpen B, Röbbecke J, Wündisch T, Stolte M, Neubauer A: Helicobacter pylori eradication therapy in gastric high grade non Hodgkin's lymphoma (NHL). Ann Hematol; 2001;80 Suppl 3:B106-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Helicobacter pylori eradication therapy in gastric high grade non Hodgkin's lymphoma (NHL).
  • BACKGROUND: Primary gastric low-grade lymphoma of the mucosa associated lymphoid tissue (MALT) develops on the background of a chronic Helicobacter pylori (H. pylori) infection.
  • Stable remissions can be induced by H. pylori eradication therapy as shown in clinical trials.
  • In 8 cases of high-grade gastric lymphomas remissions after H. pylori eradication were observed retrospectively.
  • AIM: We started a pilot-trial to investigate the value of H. pylori eradication therapy in early gastric high-grade B-cell lymphoma prospectively.
  • PATIENTS AND METHODS: So far, two H. pylori positive patients with high-grade B-cell lymphoma of the stomach stage Ann Arbor I E are included.
  • They received a triple eradication-therapy (Clarithromycin 500 mg/d, Metronidazol 800 mg/d and Omeprazol 40 mg/d) for 7 days.
  • RESULTS: Both patients became H. pylori negative after eradication therapy.
  • He presently receives chemotherapy (CHOP).
  • CONCLUSIONS: Patients with early high-grade gastric B-cell lymphomas should receive H. pylori eradication only within clinical trials.
  • It seems to be possible to induce remissions of early high-grade gastric B-cell lymphomas with exclusive H. pylori eradication therapy.
  • [MeSH-major] Anti-Ulcer Agents / therapeutic use. Clarithromycin / therapeutic use. Drug Therapy, Combination / therapeutic use. Gastritis / drug therapy. Helicobacter Infections / drug therapy. Helicobacter pylori / drug effects. Lymphoma, B-Cell, Marginal Zone / complications. Lymphoma, Non-Hodgkin / complications. Metronidazole / therapeutic use. Omeprazole / therapeutic use. Stomach Neoplasms / complications
  • [MeSH-minor] Aged. Combined Modality Therapy. Humans. Prospective Studies. Remission Induction. Treatment Outcome

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. METRONIDAZOLE .
  • Hazardous Substances Data Bank. OMEPRAZOLE .
  • Hazardous Substances Data Bank. Clarithromycin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11757689.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anti-Ulcer Agents; 140QMO216E / Metronidazole; H1250JIK0A / Clarithromycin; KG60484QX9 / Omeprazole
  •  go-up   go-down


25. Mafune KI, Tanaka Y, Suda Y, Izumo T: Outcome of patients with non-Hodgkin's lymphoma of the stomach after gastrectomy: clinicopathologic study and reclassification according to the revised European-American lymphoma classification. Gastric Cancer; 2001;4(3):137-43
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of patients with non-Hodgkin's lymphoma of the stomach after gastrectomy: clinicopathologic study and reclassification according to the revised European-American lymphoma classification.
  • BACKGROUND: The best treatment for patients with non-Hodgkin's lymphoma (NHL) of the stomach is still uncertain.
  • The revised European-American lymphoma (REAL) classification has helped to define new, potentially more appropriate classification schemes for gastric lymphomas.
  • METHODS: Fifty-one resected gastric lymphomas were reclassified according to the REAL classification, and the efficacy of multimodal treatment was examined retrospectively.
  • The principal treatment plan consisted of:.
  • (1) surgical resection of the stomach with lymph node dissection, followed by (2) systemic chemotherapy, mainly using the cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) regimen.
  • Using the REAL classification, we diagnosed diffuse large B-cell lymphoma (DLBL) in 23 patients, marginal zone B-cell (low-grade mucosa-associated lymphoid tissue [MALT]-type) lymphoma in 22, follicle center lymphoma in 4, mantle cell lymphoma in 1, and peripheral T-cell lymphoma in 1 patient.
  • Univariate analysis indicated that the tumor histology (according to the REAL classification), depth of invasion, degree of nodal involvement, Ann Arbor staging, and chemotherapy had an impact on patient outcome (P = 0.0018; P = 0.0002; P = 0.0308; P = 0.0016, and P = 0.0118, respectively).
  • CONCLUSIONS: These data reveal that gastric NHL, especially of the low-grade MALT-type, often remains localized and has a good prognosis after surgery.
  • The REAL classification was useful for classifying new categories of NHL, including the MALT-type, in the clinical setting, and for determining the optimal treatment modality for gastric NHL.
  • [MeSH-major] Lymphoma, Non-Hodgkin / pathology. Neoplasm Staging / methods. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11760079.001).
  • [ISSN] 1436-3291
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


26. Saito M, Tanaka S, Mori A, Toyoshima N, Irie T, Morioka M: Primary gastric Hodgkin's lymphoma expressing a B-Cell profile including Oct-2 and Bob-1 proteins. Int J Hematol; 2007 Jun;85(5):421-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary gastric Hodgkin's lymphoma expressing a B-Cell profile including Oct-2 and Bob-1 proteins.
  • Classic Hodgkin's lymphoma (cHL) most often involves lymph nodes, and gastric involvement is rare.
  • Hodgkin's and Reed-Sternberg (H-RS) cells in cHL are known to often lack expression of several B-lineage markers, such as CD20, CD79a, Oct-2, and Bob-1.
  • We present an extremely rare case of mixed-cellularity cHL in the stomach in which expression of these B-cells was detected immunohistochemically.
  • The patient was an 83-year-old Japanese woman who developed a sensation of abdominal fullness and appetite loss.
  • Endoscopic and abdominal computed tomography examinations revealed a gastric ulcer lesion and swelling of para-aortic lymph nodes, respectively.
  • A subtotal gastrectomy was performed, and the histopathologic diagnosis was established as a typical cHL compatible with stomach origin.
  • The patient underwent postoperative chemotherapy of 3 cycles of ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) and has since been in complete remission.
  • Our patient may have had an intermediate cHL disease overlapping that of non-Hodgkin's peripheral B-cell lymphoma, possibly reflecting derivation from germinal-center B-cells.
  • [MeSH-major] B-Lymphocytes / metabolism. Hodgkin Disease / pathology. Octamer Transcription Factor-2 / metabolism. Stomach Neoplasms / pathology. Trans-Activators / metabolism
  • [MeSH-minor] Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Biomarkers / metabolism. Bleomycin / administration & dosage. Dacarbazine / administration & dosage. Doxorubicin / administration & dosage. Female. Gastrectomy. Humans. Immunohistochemistry. Remission Induction. Vinblastine / administration & dosage

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1994 Aug 1;84(3):708-15 [8043859.001]
  • [Cites] Cancer. 2003 Aug 25;99(4):198-204 [12925980.001]
  • [Cites] J Gastroenterol. 1995 Feb;30(1):103-7 [7719402.001]
  • [Cites] Br J Haematol. 2000 Jun;109(3):584-91 [10886208.001]
  • [Cites] Blood. 2000 Dec 1;96(12):3681-95 [11090048.001]
  • [Cites] Am J Surg Pathol. 2003 Jan;27(1):16-26 [12502924.001]
  • [Cites] Arch Pathol Lab Med. 1995 Feb;119(2):163-6 [7848064.001]
  • [Cites] Blood. 2001 Jan 15;97(2):496-501 [11154228.001]
  • [Cites] Histopathology. 2005 Feb;46(2):217-28 [15693895.001]
  • [Cites] Histopathology. 2005 Jul;47(1):101-10 [15982329.001]
  • [Cites] Ann Intern Med. 1973 Jan;78(1):113-8 [4565899.001]
  • [Cites] J Pathol. 2004 Jan;202(1):60-9 [14694522.001]
  • [Cites] Am J Pathol. 1997 Oct;151(4):1123-30 [9327746.001]
  • [Cites] N Engl J Med. 1999 Apr 22;340(16):1239-47 [10210707.001]
  • [Cites] Tumori. 1992 Aug 31;78(4):280-2 [1466087.001]
  • [Cites] Blood. 2005 Jun 15;105(12):4553-60 [15728122.001]
  • [Cites] Blood. 1999 Nov 1;94(9):3108-13 [10556196.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Nov 8;91(23):10962-6 [7971992.001]
  • [Cites] Mod Pathol. 2000 Mar;13(3):223-8 [10757332.001]
  • [Cites] J Clin Oncol. 2004 Oct 15;22(20):4227-8 [15483034.001]
  • [Cites] Histopathology. 1994 Jun;24(6):511-5 [7520411.001]
  • [Cites] N Engl J Med. 1999 Nov 11;341(20):1520-9 [10559454.001]
  • [Cites] Mod Pathol. 2004 Dec;17 (12 ):1531-8 [15257313.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):2080-4 [11280769.001]
  • [Cites] Mod Pathol. 1999 Feb;12(2):200-17 [10071343.001]
  • [Cites] N Engl J Med. 1995 Oct 5;333(14):901-6 [7545266.001]
  • (PMID = 17562619.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Octamer Transcription Factor-2; 0 / POU2AF1 protein, human; 0 / Trans-Activators; 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; ABVD protocol
  •  go-up   go-down


27. Ohashi S, Segawa K, Okamura S, Urano F, Kanamori S, Hosoi T, Ishikawa H, Kanamori A, Kitabatake S, Sano H, Kobayashi T, Maeda M: Gastrin and Helicobacter pylori in low-grade MALT lymphoma patients. Scand J Gastroenterol; 2002 Mar;37(3):279-86
MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastrin and Helicobacter pylori in low-grade MALT lymphoma patients.
  • BACKGROUND: This study of patients with Helicobacter pylori infection and low-grade MALT lymphoma aimed to investigate:.
  • 1) the effect of H. pylori eradication therapy on the serum gastrin level, 2) whether changes of the serum gastrin level after therapy could predict the prognosis of patients with this tumour, and 3) the relationship between the gastric H. pylori load, the serum gastrin level and the status of MALT lymphoma.
  • METHODS: Thirteen patients with documented low-grade MALT lymphoma and H. pylori infection were enrolled and received H. pylori eradication therapy as the sole initial treatment.
  • The presence of H. pylori, the serum gastrin level, the endoscopic findings, the pathologic features of the biopsies and resected specimens, and the endoscopic ultrasonography findings were evaluated before and after therapy.
  • Successful eradication of H. pylori was followed by a decrease of the fasting serum gastrin level and complete regression of initial low-grade MALT lymphoma was observed in all patients.
  • However, two patients subsequently developed recurrent high-grade MALT lymphoma or high-grade lymphoma.
  • The median fasting serum gastrin level before H. pylori eradication therapy was higher in the patients with tumours of the gastric body (203.4 +/- 108.9 pg/ml) than in those with tumours of the antrum and angulus (89.3 +/- 28.0 pg/ml) (P = 0.06).
  • CONCLUSIONS: Hypergastrinaemia may be associated with an increased risk of gastric MALT lymphoma.
  • [MeSH-major] Anti-Bacterial Agents. Drug Therapy, Combination / administration & dosage. Gastrins / analysis. Helicobacter Infections / drug therapy. Helicobacter pylori / drug effects. Lymphoma, B-Cell, Marginal Zone / complications. Proton Pump Inhibitors
  • [MeSH-minor] Adult. Aged. Biomarkers / analysis. Female. Gastroscopy. Humans. Lymphoma, Non-Hodgkin / complications. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / therapy. Male. Middle Aged. Probability. Prognosis. Sensitivity and Specificity. Statistics, Nonparametric. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11916189.001).
  • [ISSN] 0036-5521
  • [Journal-full-title] Scandinavian journal of gastroenterology
  • [ISO-abbreviation] Scand. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Biomarkers; 0 / Gastrins; 0 / Proton Pump Inhibitors
  •  go-up   go-down


28. Sukpanichnant S, Udomsakdi-Auewarakul C, Ruchutrakool T, Leelakusolvong S, Boonpongmanee S, Chinswangwatanakul V: Gastrointestinal lymphoma in Thailand: a clinicopathologic analysis of 120 cases at Siriraj Hospital according to WHO classification. Southeast Asian J Trop Med Public Health; 2004 Dec;35(4):966-76
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastrointestinal lymphoma in Thailand: a clinicopathologic analysis of 120 cases at Siriraj Hospital according to WHO classification.
  • Clinicopathologic information of gastrointestinal (GI) lymphoma in Southeast Asia is lacking.
  • A retrospective analysis of 120 cases of GI lymphoma in Thailand diagnosed at Siriraj Hospital based on WHO classification was performed.
  • All were non-Hodgkin lymphoma (NHL).
  • Sites of involvement included stomach (49.2%), intestine (46.7%), and multiple sites (4.2%).
  • There were 104 cases of primary GI lymphoma (86.7%) and 16 cases of secondary GI lymphoma (13.3%).
  • Localized and advanced diseases were found in 68.3% and 31.7% of primary GI lymphomas, respectively.
  • The most common type of lymphoma in both groups was diffuse large B-cell lymphoma.
  • Lymphoepithelial lesions (LEL) were not significantly different between the two groups (58.2% vs 42.9%), but Helicobacterpylori infection was significantly associated with primary gastric lymphoma (p < 0.0001).
  • The treatment of choice for localized primary GI lymphoma is controversial.
  • Complete surgical resection may increase the chance of complete remission, but mortality and relapse rates might be higher than those observed with combination chemotherapy alone.
  • GI lymphomas in Thailand are mostly primary B-cell NHL.
  • LEL is not indicative of primary GI lymphoma, but H. pylori infection is closely associated with primary gastric lymphoma.
  • A prospective study to determine the treatment of choice for localized GI lymphoma is needed.
  • [MeSH-major] Lymphoma, Non-Hodgkin / pathology. Stomach Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Retrospective Studies. Thailand

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15916100.001).
  • [ISSN] 0125-1562
  • [Journal-full-title] The Southeast Asian journal of tropical medicine and public health
  • [ISO-abbreviation] Southeast Asian J. Trop. Med. Public Health
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


29. Cortelazzo S, Rossi A, Oldani E, Motta T, Giardini R, Zinzani PL, Zucca E, Gomez H, Ferreri AJ, Pinotti G, Chini C, Devizzi L, Gianni AM, Cavalli F, Barbui T, International Extranodal Lymphoma Study Group (IELSG): The modified International Prognostic Index can predict the outcome of localized primary intestinal lymphoma of both extranodal marginal zone B-cell and diffuse large B-cell histologies. Br J Haematol; 2002 Jul;118(1):218-28
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The modified International Prognostic Index can predict the outcome of localized primary intestinal lymphoma of both extranodal marginal zone B-cell and diffuse large B-cell histologies.
  • We have previously reported on the efficacy of a modified International Prognostic Index (MIPI) in predicting the outcome of patients with primary gastric lymphoma.
  • This prompted the retrospective analysis of a large series of patients with primary intestinal lymphoma (PIL) of both diffuse large B-cell (DLCL) and low-grade (extranodal marginal zone B-cell lymphoma, MZL) histology.
  • Clinical records of 122 patients with localized primary intestinal lymphoma of MZL (n=35) and DLCL (n=87) histology, confirmed by an ad hoc expert panel of pathologists, were reviewed.
  • Forty-nine patients were treated with single therapy, while 72 received combined-modality treatment, which included surgery followed by a short-term chemotherapy.
  • This retrospective study shows that stage-MIPI can be a reliable prognostic indicator for PIL of both low-grade MZL and diffuse large B-cell histology, enabling the early identification of patients at higher risk of failure.
  • [MeSH-major] Intestinal Neoplasms / therapy. Lymphoma, B-Cell / therapy. Lymphoma, Large B-Cell, Diffuse / therapy. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Male. Middle Aged. Prognosis. Regression Analysis. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12100151.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


30. Jezersek Novaković B, Vovk M, Juznic Setina T: A single-center study of treatment outcomes and survival in patients with primary gastric lymphomas between 1990 and 2003. Ann Hematol; 2006 Dec;85(12):849-56
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A single-center study of treatment outcomes and survival in patients with primary gastric lymphomas between 1990 and 2003.
  • Primary gastric lymphomas are the most common extranodal non-Hodgkin's lymphomas and are divided into indolent (low grade) and aggressive (high grade) types.
  • For several years, surgery played a central role in diagnosis, staging, and treatment of this entity, yet recently there has been a move away from a surgical approach to conservative treatment.
  • To determine the role of surgery as the initial treatment modality, we performed this retrospective single-center research on 245 patients with primary gastric lymphoma who were treated according to our protocol between 1990 and 2003.
  • The patients' characteristics, distribution of histological types, treatment results, and disease-specific survival were followed.
  • According to the histology, 59.2% had diffuse large B-cell lymphoma (DLCL), 26.1% MALT lymphoma, 9.8% mixed lymphoma (indolent and aggressive at the same time), while other types were infrequent.
  • In total, 161 patients (65.7%) were treated with surgical resection as the initial treatment, which was then followed or not by additional therapy (chemotherapy, chemotherapy and radiotherapy, radiotherapy) depending on the histological type of lymphoma and the extent of residual disease after surgery.
  • In 84 patients (34.3%), the treatment approach was conservative.
  • The selection of treatment (chemotherapy, chemotherapy and radiotherapy, radiotherapy or Helicobacter pylori eradication only) was based on the histological type of lymphoma, considering also the patients' physical condition.
  • Similarly, in the DLCL type the disease-specific survival was better in the surgically treated group (97.2%) than in the conservatively treated patients (89.2%).
  • The difference was barely significant (p=0.046) and again the results have to be considered with caution due to the selection of patients in a worse performance status or with a more extensive disease for conservative treatment.
  • In the MALT lymphoma and mixed lymphoma types, there were no differences in the disease-specific survival between both treatment groups.
  • Regarding the statement that for conservative treatment patients were selected who were unsuitable for the resection on account of concomitant diseases or due to the fact that the process was inoperable, we believe that the conservative approach gives comparable outcomes to the approach including initial surgery.
  • The existing evidence thus no longer justifies surgery as the standard initial treatment and preference should be given to conservative treatment approaches.
  • [MeSH-major] Lymphoma / mortality. Lymphoma / surgery. Stomach Neoplasms / mortality. Stomach Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Helicobacter Infections / epidemiology. Helicobacter pylori / pathogenicity. Humans. Lymphoma, B-Cell, Marginal Zone / mortality. Lymphoma, B-Cell, Marginal Zone / surgery. Lymphoma, Large B-Cell, Diffuse / mortality. Lymphoma, Large B-Cell, Diffuse / surgery. Lymphoma, Non-Hodgkin / mortality. Lymphoma, Non-Hodgkin / surgery. Male. Middle Aged. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16944146.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


31. Scholl S, Hocke M, Hoffken K, Sayer HG: Acute abdomen by varicella zoster virus induced gastritis after autologous peripheral blood stem cell transplantation in a patient with non-Hodgkin's lymphoma. Acta Haematol; 2006;116(1):58-61
Hazardous Substances Data Bank. ACYCLOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute abdomen by varicella zoster virus induced gastritis after autologous peripheral blood stem cell transplantation in a patient with non-Hodgkin's lymphoma.
  • We report on a 54-year-old male patient with an aggressive T cell non-Hodgkin's lymphoma with abdominal manifestation undergoing autologous peripheral blood stem cell transplantation after high-dose chemotherapy in April 2003.
  • About 4 months after transplantation, he developed severe upper abdominal pain.
  • Ultrasound examination, X-ray, computed tomography of the abdomen and cardiac diagnostics could not explain the symptoms.
  • While empiric therapy with high-dose acyclovir was started, we could document herpetic lesions in the gastric antrum by endoscopy.
  • The epigastric pain rapidly decreased within several days after the start of acyclovir therapy.
  • No herpetic skin lesions were observed at any time during the disease.
  • This report demonstrates the importance of viral-induced gastritis in the differential diagnosis of severe abdominal pain in patients receiving autologous peripheral blood stem cell transplantation.
  • [MeSH-major] Abdomen, Acute / drug therapy. Acyclovir / administration & dosage. Antiviral Agents / administration & dosage. Gastritis / drug therapy. Herpes Zoster / drug therapy. Herpesvirus 3, Human. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Diagnosis, Differential. Gastroscopy. Humans. Male. Middle Aged. Peripheral Blood Stem Cell Transplantation. Pyloric Antrum / virology. Transplantation, Autologous

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Shingles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16809891.001).
  • [ISSN] 0001-5792
  • [Journal-full-title] Acta haematologica
  • [ISO-abbreviation] Acta Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antiviral Agents; X4HES1O11F / Acyclovir
  •  go-up   go-down


32. Sciumè C, Geraci G, Pisello F, Li Volsi F, Facella T, Modica G: [Regression of primary low-grade gastric mucosa-associated lymphoma by eradication of Helicobacter pylori infection: case report]. Ann Ital Chir; 2004 Jan-Feb;75(1):63-8; discussion 69
Hazardous Substances Data Bank. OMEPRAZOLE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Regression of primary low-grade gastric mucosa-associated lymphoma by eradication of Helicobacter pylori infection: case report].
  • OBJECTIVE: The Authors report their experience in diagnosis and treatment of one case of primary low-grade gastric lymphoma of mucosa associated lymphoid tissue (MALT); recent international literature review.
  • Diagnostic, clinical and prognostic indication, evaluation of effectiveness of eradication therapy and short follow-up.
  • INTERVENTION: Treatment of H.
  • Disappearance and total regression of the lymphomatous tissue was observed.
  • CONCLUSIONS: Our reports confirm the recent anecdotal reports on regression of gastric MALT lymphoma after eradication of H.
  • [MeSH-major] Anti-Bacterial Agents / therapeutic use. Anti-Ulcer Agents / therapeutic use. Helicobacter Infections / drug therapy. Helicobacter pylori. Lymphoma, B-Cell, Marginal Zone / microbiology. Lymphoma, Non-Hodgkin / microbiology. Omeprazole / analogs & derivatives. Stomach Neoplasms / microbiology
  • [MeSH-minor] 2-Pyridinylmethylsulfinylbenzimidazoles. Aged. Amoxicillin / therapeutic use. Female. Humans. Lansoprazole. Metronidazole / therapeutic use. Treatment Outcome

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • MedlinePlus Health Information. consumer health - Antibiotics.
  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. AMOXICILLIN .
  • Hazardous Substances Data Bank. METRONIDAZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15283390.001).
  • [ISSN] 0003-469X
  • [Journal-full-title] Annali italiani di chirurgia
  • [ISO-abbreviation] Ann Ital Chir
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / 2-Pyridinylmethylsulfinylbenzimidazoles; 0 / Anti-Bacterial Agents; 0 / Anti-Ulcer Agents; 0K5C5T2QPG / Lansoprazole; 140QMO216E / Metronidazole; 804826J2HU / Amoxicillin; KG60484QX9 / Omeprazole
  • [Number-of-references] 24
  •  go-up   go-down


33. Kirsch C, Breidert M, Nagel M, Kessler U, Kittner T, Gaertner HJ, Ehninger G: [Secondary high-grade MALT lymphoma of the stomach in a 69-year-old patient with gastrocolic fistula]. Z Gastroenterol; 2001 Jan;39(1):77-81
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Secondary high-grade MALT lymphoma of the stomach in a 69-year-old patient with gastrocolic fistula].
  • [Transliterated title] Sekundär hoch malignes MALT-Lymphom des Magens bei einem 69-jährigen Patienten mit gastrokolischer Fistel.
  • Upper endoscopy had been performed prior by an outpatient gastroenterologist and the patient had received an eradication therapy for a Helicobacter pylori-induced gastritis.
  • At admission upper endoscopy showed a gastric ulcer which drained a stinking fluid.
  • Endosonography, computed tomography and an upper gastrointestinal series with water soluble media revealed a gastrocolic fistula.
  • Multiple biopsies showed a low-grade gastric MALT lymphoma.
  • The histology of the completely removed stomach revealed a high-grade Non Hodgkin Lymphoma (NHL) with parts of a low-grade NHL.
  • 3 weeks after surgery chemotherapy was started with the CHOP-regime which was well-tolerated by the patient.
  • [MeSH-major] Colonic Diseases / diagnosis. Gastric Fistula / diagnosis. Helicobacter Infections / diagnosis. Helicobacter pylori. Intestinal Fistula / diagnosis. Lymphoma, B-Cell, Marginal Zone / diagnosis. Peptic Ulcer Perforation / diagnosis. Stomach Neoplasms / diagnosis. Stomach Ulcer / diagnosis
  • [MeSH-minor] Aged. Gastrectomy. Gastric Mucosa / pathology. Gastroscopy. Humans. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / pathology. Lymphoma, Non-Hodgkin / surgery. Male. Tomography, X-Ray Computed


34. Martinelli G, Laszlo D, Ferreri AJ, Pruneri G, Ponzoni M, Conconi A, Crosta C, Pedrinis E, Bertoni F, Calabrese L, Zucca E: Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy. J Clin Oncol; 2005 Mar 20;23(9):1979-83
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy.
  • PURPOSE: Preliminary results using rituximab in extranodal marginal zone (MALT) non-Hodgkin's lymphoma (NHL) patients seem to indicate a relevant clinical activity.
  • Aim of the present study is to investigate the efficacy of conventional weekly treatment using rituximab in gastric MALT NHL patients resistant/refractory or not suitable for eradication treatment, and to evaluate the relevance of the t(11; 18)(q21;.
  • PATIENTS AND METHODS: Twenty-seven patients presenting with gastric MALT NHL at any stage, relapsed/refractory to initial treatment or not suitable for eradication were treated with rituximab in a weekly conventional schedule and evaluated for response and relapse.
  • CONCLUSION: Our experience seems to confirm the clinical activity of rituximab in gastric MALT NHL patients resistant/refractory to antibiotics treatment or not presenting with clinical evidence of Helicobacter pylori infection.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Lymphoma, B-Cell, Marginal Zone / drug therapy. Lymphoma, Non-Hodgkin / drug therapy. Stomach Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2005 Oct 10;23(29):7361-2; author reply 7362-3 [16210674.001]
  • (PMID = 15668468.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


35. Luo ZG, Feng FY, Zhang P, Wang XY, Wang QL: [Clinical analysis of 68 patients with primary gastric lymphoma]. Ai Zheng; 2004 Dec;23(12):1692-5
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of 68 patients with primary gastric lymphoma].
  • BACKGROUND & OBJECTIVES: Stomach is the most common extranodal involvement site of lymphoma.
  • Treatment patterns for primary gastric lymphoma (PGL) are controversial now.
  • This study was to investigate clinical features, treatment patterns, and prognostic factors of patients with PGL.
  • Thirty-seven patients received surgery plus chemotherapy,7 received surgery plus chemoradiotherapy,9 received surgery plus radiotherapy,9 received surgery plus chemotherapy, 4 received surgery alone,and 2 were untreated.
  • Common lesions of PGL were in gastric body, and gastric antrum.
  • All 68 patients with PGL were diagnosed of non-Hodgkin's lymphoma (NHL) by pathology, which constituted about 3.4% of all gastric malignancies synchronously, 1 was T cell original, 67 were B cell original.
  • CONCLUSIONS: Treatment of PGL should be based on combined therapy of surgery, chemotherapy, and radiotherapy.
  • [MeSH-major] Gastrectomy. Lymphoma, Non-Hodgkin / surgery. Stomach Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Prednisone / therapeutic use. Prognosis. Proportional Hazards Models. Radiotherapy, High-Energy. Retrospective Studies. Survival Rate. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15601562.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


36. Begum S, Sano T, Endo H, Kawamata H, Urakami Y: Mucosal change of the stomach with low-grade mucosa-associated lymphoid tissue lymphoma after eradication of Helicobacter pylori: follow-up study of 48 cases. J Med Invest; 2000 Feb;47(1-2):36-46
Hazardous Substances Data Bank. OMEPRAZOLE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucosal change of the stomach with low-grade mucosa-associated lymphoid tissue lymphoma after eradication of Helicobacter pylori: follow-up study of 48 cases.
  • Low-grade mucosa-associated lymphoid tissue (MALT) lymphoma of the stomach has been demonstrated to be closely linked to Helicobacter pylori (H. pylori) and to be frequently remissioned after the cure of H. pylori infection.
  • Several previous studies have focused on proliferating lymphocytes but little is known about gastric epithelial change and the duration of the remission after the cure of H. pylori infection.
  • We performed a long-term follow-up investigation on the effects of anti-H. pylori treatment on MALT lymphoma and chronic gastritis at the histologic and molecular levels.
  • Forty-eight patients with low-grade gastric MALT lymphoma and 28 chronic gastritis patients in whom H. pylori infection was eradicated were studied.
  • After eradication, 43 MALT lymphoma patients showed complete histologic remission and continuous remission was observed during follow-up for up to 43 months (mean, 17.8 months).
  • As for epithelial changes after eradication, "emptiness of lamina propria" was more pronounced in the mucosa with MALT lymphoma than that with chronic gastritis, and its severity in MALT lymphoma cases significantly decreased during the observation period whereas the glandular area increased.
  • Cystic change of the fundic gland also occurred more frequently in MALT lymphoma cases than chronic gastritis cases.
  • B-cell clonality before eradication analyzed by reverse transcriptase-polymerase chain reaction (RT-PCR) was detected in almost all MALT lymphoma cases (43 cases), but rare in chronic gastritis cases (6 cases).
  • After eradication, in spite of histologic regression, 21 MALT lymphoma patients had a persistent monoclonal population during the follow-up period.
  • B-cell monoclonality preceding the malignant transformation was noted in 4 cases.
  • These observations indicate that 1) complete histologic remission of low-grade gastric MALT lymphomas seems stable even if a monoclonal B cell population is detectable in some cases, 2) there may be a stage of disease where monoclonal B cells are present but there is no histologic evidence of MALT lymphoma, and 3) regenerative change of the damaged glands may occur in histologic regressed MALT lymphoma cases.
  • [MeSH-major] Helicobacter Infections / pathology. Helicobacter pylori. Lymphoma, B-Cell, Marginal Zone / pathology. Lymphoma, Non-Hodgkin / pathology. Stomach / pathology. Stomach Neoplasms / pathology
  • [MeSH-minor] 2-Pyridinylmethylsulfinylbenzimidazoles. Adult. Aged. Amoxicillin. Drug Therapy, Combination. Female. Follow-Up Studies. Gastric Mucosa / microbiology. Gastric Mucosa / pathology. Humans. Lansoprazole. Male. Metronidazole. Middle Aged. Omeprazole / analogs & derivatives. Reverse Transcriptase Polymerase Chain Reaction / methods

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. AMOXICILLIN .
  • Hazardous Substances Data Bank. METRONIDAZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10740978.001).
  • [ISSN] 1343-1420
  • [Journal-full-title] The journal of medical investigation : JMI
  • [ISO-abbreviation] J. Med. Invest.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] JAPAN
  • [Chemical-registry-number] 0 / 2-Pyridinylmethylsulfinylbenzimidazoles; 0K5C5T2QPG / Lansoprazole; 140QMO216E / Metronidazole; 804826J2HU / Amoxicillin; KG60484QX9 / Omeprazole
  •  go-up   go-down


37. Doglioni C, Savio A, Ranaldi R, Magrini U, GIPAD. Gruppo Italiano Patologi dell'Apparato Digerente: [Stomach lymphomas: minimum diagnostic requirements for gastrointestinal histopathological diagnosis]. Pathologica; 2001 Feb;93(1):61-70
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Stomach lymphomas: minimum diagnostic requirements for gastrointestinal histopathological diagnosis].
  • Gastric lymphomas have been the subject of intensive studies in the last years and important progress has been made regarding their etiopathogenesis and therapy.
  • Diagnosis of gastric lymphoma is usually made on bioptic material taken at endoscopy.
  • It analyses the morphological, immunohistochemical and molecular features to be considered for the differential diagnosis between: reactive process vs low grade B-cell gastric MALT lymphoma, B-cell MALT lymphoma vs other low grade lymphomas involving the stomach and low grade vs high grade gastric lymphoma.
  • The histopathological aspects of gastric biopsies after antibiotic treatment for Helicobacter pylori eradication and the role of molecular analysis in the follow-up of these patients are also considered.
  • [MeSH-major] Lymphoma, Non-Hodgkin / diagnosis. Stomach Neoplasms / diagnosis
  • [MeSH-minor] Algorithms. Gastritis / complications. Gastritis / diagnosis. Gastritis / drug therapy. Gastritis / microbiology. Helicobacter Infections / complications. Helicobacter Infections / diagnosis. Helicobacter Infections / drug therapy. Helicobacter pylori / drug effects. Lymphoma, B-Cell, Marginal Zone / diagnosis. Lymphoma, B-Cell, Marginal Zone / etiology. Lymphoma, B-Cell, Marginal Zone / pathology. Lymphoma, B-Cell, Marginal Zone / prevention & control. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, T-Cell / diagnosis. Lymphoma, T-Cell / pathology. Precancerous Conditions / drug therapy. Precancerous Conditions / microbiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11294022.001).
  • [ISSN] 0031-2983
  • [Journal-full-title] Pathologica
  • [ISO-abbreviation] Pathologica
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 17
  •  go-up   go-down






Advertisement